ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program
17 janv. 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study
07 janv. 2019 07h00 HE
|
ContraFect Corporation
Proof of concept that new class of lysin biologics has the potential to improve treatment outcomes in serious bacterial infections Exebacase demonstrated robust safety and tolerability profile ...
ContraFect to Present at Biotech Showcase 2019
20 déc. 2018 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Dec. 20, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Piper Jaffray Health Care Conference
19 nov. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 19, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Appoints Michael Messinger as Chief Financial Officer
12 nov. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces Third Quarter 2018 Financial Results
08 nov. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes
01 nov. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Participate in World Antimicrobial Resistance Congress 2018
22 oct. 2018 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 (exebacase) at IDWeek 2018
25 sept. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 25, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Two Upcoming Investor Conferences
20 sept. 2018 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...